Replies to post #249719 on Biotech Values

[DewDiligence]

Diagnostics is a tough business in which to make money. EXAS lost $150M during the first nine months of 2023 (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001124140/000112414023000090/exas-20230930.htm#i8b4370ac6f1e49f798da127a92ff7f47_16 ), despite Cologuard’s having been on the US market since 2014.